共 52 条
[1]
Bailey CJ(2017)Metformin: historical overview Diabetologia 60 1566-1576
[2]
Davies MJ(2022)Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 67 587-597
[3]
Aroda VR(2007)Sitagliptin Drugs 29 2632-2637
[4]
Collins BS(2006)Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 63 663-674
[5]
Lyseng-Williamson KA(2014)Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and “isoglycemic” intravenous glucose Diabetes 29 2638-2643
[6]
Aschner P(2006)Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care 37 699-708
[7]
Kipnes MS(2012)Sitagliptin/metformin (Janumet) as combination therapy in the treatment of type-2 diabetes mellitus Pharmacy Therapeutics 22 1939-1947
[8]
Lunceford JK(2006)Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes Curr Med Res Opin 6 25-37
[9]
Vardarli I(2013)Safety and efficacy of sitagliptin–metformin in fixed combination for the treatment of type 2 diabetes mellitus Clin Med Insights: Endocrinol Diabetes 71 349-361
[10]
Arndt E(2011)Sitagliptin/metformin fixed-dose combination. In patients with type 2 diabetes mellitus Drugs 28 307-313